Abstract 4564
Background
The current standard-of-care first-line therapy for patients (pts) with recurrent/metastatic cervical cancer (r/mCC) is paclitaxel/platinum ± bevacizumab (BEV). However, approximately 50% of pts who are eligible to receive this regimen do not respond to the treatment. Tissue factor (TF) is highly expressed in cervical cancer and is associated with poor prognosis. Tisotumab vedotin (TV) is an investigational first-in-class antibody-drug conjugate comprising a fully human monoclonal antibody targeting TF conjugated to the microtubule-disrupting agent monomethyl auristatin E via a protease-cleavable linker. Single-agent TV demonstrated encouraging antitumor activity (independent review committee–assessed confirmed ORR, 22%; median DOR, 6.0 mo) and a manageable safety profile in pts with previously treated r/mCC. innovaTV 205/ENGOT-cx8 (NCT03786081; GOG-3024) is a global, multicenter, open-label, phase 1/2 trial evaluating the safety and antitumor activity of TV in combination with BEV, pembrolizumab (PEM), or carboplatin (CBP) in pts with untreated and previously treated r/mCC. Results from the innovaTV 205 study will inform the further clinical development of TV in cervical cancer.
Trial design
Approximately 140 adult pts with recurrent or stage IVB squamous, adenosquamous, or adenocarcinoma of the cervix; measurable disease; and ECOG PS 0-1 will be enrolled. The phase 1 portion of the study will consist of 3 dose escalation cohorts for identification of the recommended phase 2 dose (RP2D) of TV with BEV, PEM, or CBP. The phase 2 portion will include 3 expansion cohorts. In the dose escalation cohorts, previously treated pts will receive escalating doses of TV (IV 1Q3W) in combination with escalating doses of BEV (IV 1Q3W), a fixed dose of PEM (IV 1Q3W), or a fixed dose of CBP (IV 1Q3W). In the expansion cohorts, pts who have not received prior systemic therapy for r/mCC will receive 1) TV RP2D + PEM or 2) TV RP2D + CBP; pts who received 1-2 prior treatments for r/mCC will receive TV RP2D + PEM. Additional cohorts might be added. The primary endpoint of phase 2 is ORR (RECIST v1.1). Secondary endpoints include DOR, time to response, PFS, OS, and safety.
Clinical trial identification
NCT03786081; GOG-3024.
Editorial acknowledgement
ApotheCom, San Francisco, CA, USA.
Legal entity responsible for the study
Genmab.
Funding
Genmab.
Disclosure
I.B. Vergote: Advisory / Consultancy: Advaxis; Advisory / Consultancy: Eisai; Advisory / Consultancy: MSD Belgium; Advisory / Consultancy: Roche NV; Advisory / Consultancy, Research grant / Funding (self): Genmab; Advisory / Consultancy: F. Hoffmann-La Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: PharmaMar; Advisory / Consultancy: Millennium; Advisory / Consultancy: Clovis; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: Tesaro; Advisory / Consultancy, Research grant / Funding (self): Oncoinvent; Advisory / Consultancy: Immunogen; Research grant / Funding (self): Amgen; Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Research grant / Funding (self): Stichting Tegen Kanker; Travel / Accommodation / Expenses: Takeda. N. Concin: Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: AstraZeneca; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Genmab; Travel / Accommodation / Expenses: Amgen. M.R. Mirza: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self): Biocad; Honoraria (self), Research grant / Funding (institution): Clovis; Honoraria (self): Geneos; Honoraria (self): Genmab; Honoraria (self): Karyopharm; Honoraria (self): Merck; Honoraria (self): Oncology Venture; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Seattle Genetics; Honoraria (self): Sera Prognostics; Honoraria (self): Sotio; Honoraria (self), Research grant / Funding (institution): Tesaro; Honoraria (self): ZaiLab; Research grant / Funding (institution): Boehringer Ingelheim. A. Malmberg: Full / Part-time employment: Genmab. L. Eaton: Full / Part-time employment: Genmab. L. Nicacio: Full / Part-time employment: Seattle Genetics. D. Lorusso: Advisory / Consultancy, Research grant / Funding (institution): Tesaro; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): Clovis; Advisory / Consultancy: Merrimack. I. Soumaoro: Full / Part-time employment: Genmab. B.J. Monk: Honoraria (self), Advisory / Consultancy, Oncomed (honoraria/consultant): AbbVie; Honoraria (institution), Advisory / Consultancy, Oncoquest (honoraria/consultant): Advaxis; Honoraria (self), Advisory / Consultancy, Oncosec (honoraria/consultant): Agenus; Honoraria (self), Advisory / Consultancy, Perthera (honoraria/consultant): Amgen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Pfizer (honoraria/consultant): AstraZeneca; Honoraria (self), Advisory / Consultancy, Precision Oncology (honoraria/consultant): ChemoCare; Honoraria (self), Advisory / Consultancy, Puma (honoraria/consultant): ChemoID; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Roche/Genentech (honoraria/speaker/consultant): Clovis; Honoraria (self), Advisory / Consultancy, Samumed (honoraria/consultant): Conjupro; Honoraria (self), Advisory / Consultancy, Takeda (honoraria/consultant): Eisai; Honoraria (self), Advisory / Consultancy, Vesaro (honoraria/speaker/consultant): Geistlich; Honoraria (self), Advisory / Consultancy, VBL (honoraria/consultant): Genmab; Honoraria (self), Advisory / Consultancy: ImmunoGen; Honoraria (self), Advisory / Consultancy: Immunomedics; Honoraria (self), Advisory / Consultancy: Incyte; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Janssen/J&J; Honoraria (self), Advisory / Consultancy: Mateon (formerly Oxigene); Honoraria (self), Advisory / Consultancy: Merck; Advisory / Consultancy: Myriad; Honoraria (self), Advisory / Consultancy: Nucana. D.M. O’Malley: Advisory / Consultancy, Research grant / Funding (institution), Officer / Board of Directors, Ergomed Clinical Research (research support - institution): Clovis; Advisory / Consultancy, Research grant / Funding (institution), Exelixis (research support - institution): AstraZeneca; Advisory / Consultancy, Henry Jackson Foundation (research support - institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution), Genentech (research support - institution): Gynecologic Oncology Group; Advisory / Consultancy, GSK (research support - institution): Myriad; Advisory / Consultancy, Research grant / Funding (institution), INC Research (research support - institution): Tesaro; Advisory / Consultancy, inVentiv Health Clinical (research support - institution): Novocure; Advisory / Consultancy, Janssen Research and Development (research support - institution): Translational Genomics/Cordgenics; Officer / Board of Directors, Ludwig Institute for Cancer Research (research support - institution): Novocure; Officer / Board of Directors, Novartis (research support - institution): Amgen; Research grant / Funding (institution), Officer / Board of Directors, PharmaMar (research support - institution): Immunogen; Advisory / Consultancy, Research grant / Funding (institution), Pfizer (research support - institution): AbbVie; Advisory / Consultancy, PRA International (research support - institution): Health Analytics; Advisory / Consultancy, Regeneron (research support - institution): Ambry; Research grant / Funding (institution), Sanofi (research support - institution): Advaxis; Research grant / Funding (institution), Serono (research support - institution): Agenus; Research grant / Funding (institution), Stemcentrx (research support - institution): Ajinomoto; Research grant / Funding (institution), Tracon (research support - institution): Array BioPharma; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Eisai.
Resources from the same session
3516 - Palbociclib Rechallenge in Hormone Receptor (HR)[+]/HER2[-] Advanced Breast Cancer (ABC). PALMIRA Trial
Presenter: Antonio Llombart Cussac
Session: Poster Display session 2
Resources:
Abstract
4616 - Alpelisib (ALP) + Endocrine Therapy (ET) by Last Prior Therapy in Patients (pts) With PIK3CA-Mutated Hormone-Receptor Positive (HR+) Human Epidermal Growth Factor Receptor-2-Negative (HER2–) Advanced Breast Cancer (ABC): Additional Study Cohort in BYLieve
Presenter: Eva Ciruelos
Session: Poster Display session 2
Resources:
Abstract
3592 - PRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Presenter: Tom Degenhardt
Session: Poster Display session 2
Resources:
Abstract
4168 - Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and platinum sensitive recurrent ovarian cancer
Presenter: Ning Li
Session: Poster Display session 2
Resources:
Abstract
2785 - Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase 3 study ARIEL3 of rucaparib maintenance treatment
Presenter: Jonathan Ledermann
Session: Poster Display session 2
Resources:
Abstract
3496 - Integrated safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings
Presenter: Rebecca Kristeleit
Session: Poster Display session 2
Resources:
Abstract
2844 - Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
Presenter: S.Intidhar Labidi-Galy
Session: Poster Display session 2
Resources:
Abstract
1955 - A Prospective Evaluation of Tolerability of Niraparib Dosing Based on Baseline Body Weight (BW) and Platelet (plt) Count: Blinded Pooled Interim Safety Data from the NORA Study
Presenter: Xiaohua Wu
Session: Poster Display session 2
Resources:
Abstract
2539 - Evaluation of Niraparib 200 mg/d as Maintenance Therapy in Recurrent Ovarian Cancer and Associated Thrombocytopenia in a Real-World US Setting
Presenter: Premal Thaker
Session: Poster Display session 2
Resources:
Abstract
1290 - Niraparib initial dose and its’ management in patients with recurrent high-grade serous ovarian cancer.
Presenter: Jacek Grabowski
Session: Poster Display session 2
Resources:
Abstract